Patents Assigned to Biognostik Ges. fur biomolekulare Diagnostik mbH
  • Antisense oligonucleotide preparation method
    Patent number: 7563778
    Abstract: A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: July 21, 2009
    Assignee: Biognostik Ges. fur biomolekulare Diagnostik mbH
    Inventors: Karl-Hermann Schlingensiepen, Wolfgang Brysch
  • Antisense oligonucleotide preparation method
    Patent number: 6972171
    Abstract: A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: December 6, 2005
    Assignee: Biognostik Ges. fur biomolekulare Diagnostik mbH
    Inventors: Karl-Hermann Schlingensiepen, Wolfgang Brysch